**Session Title:** ASCO/American Association for Cancer Research (AACR) Joint Session: Immunotherapy--A Strategy Whose Time Has (Finally) Come  
**Session Type:** Special Session  
**Time:** 8:00 AM - 9:15 AM  
**Location:** S100a

- Welcome and Introduction  
  *Michael Paul Link, MD (Co-Chair)*
- Chimeric Antigen Receptors: Engineering Designer T cells for Cancer Therapy  
  *Carl H. June, MD*
- Immune Checkpoint Blockade: Unleashing the Immune System against Melanoma and Beyond  
  *Suzanne Louise Topalian, MD*
- Mechanisms of Protective Immunity: Building on Success  
  *Glenn Dranoff, MD*
- Closing Remarks  
  *Judy Ellen Garber, MD, MPH (Co-Chair)*

---

**Session Title:** "Personalized" Oncology for Colorectal Cancer: Ready for Prime Time or Stop the Train?  
**Session Type:** Education Session  
**Time:** 8:00 AM - 9:15 AM  
**Location:** S406

- Personalized Colorectal Cancer Medicine  
  *Alan Paul Venook, MD (Chair)*
- Pro: Colorectal Cancer Treatment Is Ready for Personalization—Why Is It Not Being Used Enough?  
  *Johanna C. Bendell, MD*
- Con: Lots of Data Out There But Not Enough to Direct Patient Care  
  *Robert S. Warren, MD*

---

**Session Title:** Imaging in Neuro-oncology: Practical Primer for the Practicing Physician  
**Session Type:** Education Session  
**Time:** 8:00 AM - 9:15 AM  
**Location:** S100bc

- Before Functional Imaging, There Was MRI: A Twenty-First Century Review of Conventional MRI in Your Clinic  
  *Whitney Pope, MD, PhD*
- In the Post-operative and Post-radiation Setting, How Do/Should We Use MRI and Functional Imaging?  
  *Susan Marina Chang, MD (Chair)*
- Recurrent Gliomas Don't All Look Alike: Imaging of Recurrence on Antiangiogenic versus Other Chemotherapies  
  *Andrew David Norden, MD, MPH*

---

**Session Title:** Kidney Cancer Biology and Therapeutics: VEGFR, mTOR, and Beyond  
**Session Type:** Education Session  
**Time:** 8:00 AM - 9:15 AM  
**Location:** E Arie Crown Theater

- Molecular Biology of Renal Cell Carcinoma: Therapeutic Implication  
  *James Brugarolas, MD, PhD*
• First-Line Therapy for Renal Cell Cancer  
  *Daniel Yick Chin Heng, MD, MPH*

• Systemic Therapy for Advanced Renal Cell Cancer after Failure of a First-Line Targeted Therapy  
  *Toni K. Choueiri, MD (Chair)*

**Session Title:** Molecular Pathways for the Practicing Pediatric Oncologist  
**Session Type:** Education Session  
**Time:** 8:00 AM - 9:15 AM  
**Location:** S504

• Finding the Needles in the Haystack: The Promise and Limitations of Next-Generation Sequencing  
  *Donald W. Parsons, MD, PhD (Chair)*

• Why IGF Signaling Inhibition Is Not as Easy as It Should Be  
  *Katia Scotlandi, PhD*

• Hedgehog Pathway in Pediatric Cancers: They're Not Just for Brain Tumors Anymore  
  *Tobey MacDonald, MD*

**Session Title:** Patients with HPV-Positive Oropharynx Tumors: Communicating Diagnosis to Family and Treatment Options  
**Session Type:** Education Session  
**Time:** 8:00 AM - 9:15 AM  
**Location:** E354a

• Molecular Pathology and Identification of HPV-Positive Tumor  
  *William H. Westra, MD*

• HPV Transmission with Focus on Implications for Sexual Partner  
  *Maura L. Gillison, MD, PhD*

• Management of HPV-Positive Tumor  
  *David M. Brizel, MD (Chair)*

**Session Title:** Highlights of the Day III Session  
**Session Type:** Highlights of the Day  
**Time:** 8:00 AM - 9:30 AM  
**Location:** E Hall D1

• Chair  
  *Douglas Yee, MD*

• Lung Cancer - Non-small Cell Metastatic  
  *Thomas James Lynch, MD*

• Lung Cancer - Non-small Cell Local-Regional/Small Cell/Other Thoracic Cancers  
  *Heather A. Wakelee, MD*

• Cancer Prevention/Epidemiology  
  *Carol J. Fabian, MD*

• Patient and Survivor Care  
  *Debra L. Barton, PhD, AOCN, RN*

• Melanoma/Skin Cancers  
  *Jeffrey Alan Sosman, MD*

• Sarcoma  
  *Christopher W. Ryan, MD*

**Session Title:** Health Services Research  
**Session Type:** Poster Discussion Session  
**Display Time:** 8:00 AM - 12:00 PM  
**Display Location:** S405
**Discussion Time:** 11:30 AM - 12:30 PM  
**Discussion Location:** S406

- **Co-Chair**
  
  *Aileen B. Chen, MD*

- **Co-Chair**
  
  *Steven J. Katz, MD, MPH*

---

Brd. 1
- Toxicity of chemotherapy dosing using actual body weight in obese versus normal-weight patients: A systematic review and meta-analysis. (Abstract #6013)  
  
  *Kathryn Cunningham Hourdequin*

Brd. 2
- Adjuvant chemotherapy (AC) initiation and early discontinuation in elderly patients (EPs) with stage III colon cancer (CC). (Abstract #6014)  
  
  *Jenny J Ko*

Brd. 3
- Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC). (Abstract #6015)  
  
  *Heidi D. Klepin*

Brd. 4
- Refused versus recommended adjuvant chemotherapy in the United States: A reason for concern. (Abstract #6016)  
  
  *Elizabeth Butzer Habermann*

Brd. 5
- Endocrine therapy use among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. (Abstract #6017)  
  
  *Racquel Elizabeth Kohler*

Brd. 6
- Use of palliative chemotherapy and targeted agents in elderly patients with metastatic colorectal cancer (mCRC). (Abstract #6018)  
  
  *Matthew Chan*

- **Discussion**
  
  *Sharon Hermes Giordano, MD, MPH*

Brd. 7
- An assessment of the collective efforts of clinical trials to provide evidence-based practice guidelines in cancer care. (Abstract #6019)  
  
  *Shane Lloyd*

Brd. 8
- A critical evaluation of oncology clinical practice guidelines. (Abstract #6020)  
  
  *Bradley Norman Reames*

Brd. 9
- Cancer patients’ trade-offs for efficacy, toxicity, and cost. (Abstract #6021)  
  
  *Yu-Ning Wong*

Brd. 10
- Tradeoffs associated with axillary lymph node dissection: Implications of the eligibility versus enrollment in ACOSOG Z0011. (Abstract #6022)  
  
  *Monica Shalini Krishnan*

Brd. 11
- The involvement of partners in breast cancer treatment decision making. (Abstract #6023)  
  
  *Sarah T. Hawley*
• Improving the quality of breast cancer surgical treatment decisions. (Abstract #6024)
  
  Steven J. Katz

Brd. 13
• Does unblinding of treatment assignment impact participant perceptions in clinical trials? (Abstract #6025)
  
  Ann H. Partridge
• Discussion
  
  Stephen B. Edge, MD

Brd. 14
• Is care coordination associated with improved care quality for comorbid conditions in cancer survivors? (Abstract #6026)
  
  Claire Frances Snyder

Brd. 15
• Patterns of diagnostic imaging and cumulative radiation exposure among long-term young adult cancer survivors. (Abstract #6027)
  
  Corinne Daly

Brd. 16
• How do elderly cancer survivors fare? A comparison of characteristics, health status, health behaviors, and spending between Medicare beneficiaries with and without a cancer history. (Abstract #6028)
  
  Xuehua Ke

Brd. 17
• Patient-centered medical homes may improve breast cancer surveillance among survivors. (Abstract #6029)
  
  Stephanie B. Wheeler

Brd. 18
• Longitudinal changes in health care utilization by adult survivors of childhood cancer in the Childhood Cancer Survivor Study (CCSS). (Abstract #6030)
  
  Jacqueline N. Casillas
• Discussion
  
  Lynne I. Wagner, PhD

Brd. 19
• How radiation oncologist accessibility influences treatment choice and quality in early stage breast cancer: A SEER database analysis. (Abstract #6031)
  
  Thomas M. Churilla

Brd. 20
• Life expectancy (LE) and the receipt of conservative versus active treatment in men with prostate cancer (CaP): A population-based study. (Abstract #6032)
  
  Trevor Joseph Royce

Brd. 21
• Timeliness of care and stage at diagnosis of non-small cell lung cancer (NSCLC) with the implementation of a cancer care coordination program (CCCP) at a VA medical center. (Abstract #6033)
  
  Susan Alsamarai

Brd. 22
• Do patients with advanced stage non-small cell lung cancer (AS NSCLC) live longer if managed within a clinical trial setting? (Abstract #6034)
  
  Taher Abu Hejleh
Brd. 23
• Results of a cluster randomized trial to evaluate a nursing lead supportive care intervention in newly diagnosed breast and colorectal cancer patients. (Abstract #6035)
  
  Jonathan Sussman

Brd. 24
• Which women with breast cancer do, and do not, undergo receptor status testing? A population-based study. (Abstract #6036)
  
  Linda Sharp

Brd. 25
• Racial differences in delay of treatment for localized prostate cancer (CaP): A population-based study. (Abstract #6037)
  
  William Allen Stokes

• Discussion
  
  Michael J. Hassett, MD, MPH

---

**Session Title:** Lung Cancer - Non-small Cell Metastatic  
**Session Type:** Poster Discussion Session  
**Display Time:** 8:00 AM - 12:00 PM  
**Display Location:** E450a  
**Discussion Time:** 11:30 AM - 12:30 PM  
**Discussion Location:** E354a

- Co-Chair
  
  Bryan J. Schneider, MD

- Co-Chair
  
  Alan Sandler, MD

Brd. 1
• A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29. (Abstract #7511)
  
  Scott Andrew Laurie

Brd. 2
• Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced non-squamous NSCLC. (Abstract #7512)
  
  Suresh S. Ramalingam

Brd. 3
• CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). (Abstract #7513)
  
  Rebecca Suk Heist

Brd. 4
• Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RTD). (Abstract #7514)
  
  Beth A. Hellerstedt

Brd. 5
• Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701). (Abstract #7515)
  
  Nobuyuki Katakami
Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). (Abstract #7516)

Nasser H. Hanna

Discussion

Benjamin Besse, MD, PhD

SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). (Abstract #7517)

Howard Jack West

Randomized phase II trial of erlotinib (E) plus high-dose celecoxib (HD-C) or placebo (P) in advanced non-small cell lung cancer. (Abstract #7518)

Karen L. Reckamp

A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. (Abstract #7519a)

Tony Mok

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). (Abstract #7520)

Caicun Zhou

Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). (Abstract #7521)

Tetsuya Mitsudomi

EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study. (Abstract #7522)

Rafael Rosell

Sensitivity to EGFR inhibitors based on location of EGFR exon 20 insertion mutations within the tyrosine kinase domain of EGFR. (Abstract #7523)

Daniel Botelho Costa

Discussion

Roman Perez-Soler, MD

Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI). (Abstract #7524)

Sarah B. Goldberg
• Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance. (Abstract #7525)
  Stephanie Heon

• Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC). (Abstract #7526)
  Andrew James Weickhardt

• Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. (Abstract #7527)
  Helena Alexandra Yu

• Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and -negative populations. (Abstract #7528)
  Akito Hata

• Discussion
  Howard Jack West, MD

• Concordance of driver mutations in primary and matched metastasis from patients with non-small cell lung cancer (NSCLC) using next-generation sequencing (NGS). (Abstract #7529)
  Stéphane Vignot

• First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers. (Abstract #7530)
  Mark G. Kris

• A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. (Abstract #7531)
  Gregory J. Riely

• Characteristics of NSCLCs harboring NRAS mutations. (Abstract #7532)
  Kadoaki Ohashi

• Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). (Abstract #7533)
  Dong-Wan Kim

• Native and rearranged ALK copy number and rearranged ALK cell count in NSCLC: Implications for ALK inhibitor therapy. (Abstract #7534)
  D. Ross Camidge

• Discussion
  Fiona Hellen Blackhall, MBChB, MRCP, PhD

Session Title: Tumor Biology
Session Type: Poster Discussion Session
Display Time: 8:00 AM - 12:00 PM
Display Location: S102
Discussion Time: 11:30 AM - 12:30 PM
Discussion Location: S100a
• Co-Chair  
  Kapil N. Bhalla, MD  
• Co-Chair  
  Cynthia X. Ma, MD, PhD  

Brd. 1  
• Next-generation RNA sequencing reveals transcriptomic changes after brief exposure to preoperative nab-paclitaxel, bevacizumab, and trastuzumab. (Abstract #10508)  
  Vinay Varadan  

Brd. 2  
• Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008). (Abstract #10509)  
  Roisin M. Connolly  

Brd. 3  
• PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations. (Abstract #10510)  
  Filip Janku  

Brd. 4  
• Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype. (Abstract #10511)  
  Leticia De Mattos -Arruda  

Brd. 5  
• Dynamic contrast-enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer. (Abstract #10512)  
  Jesus Garcia-Foncillas  

Brd. 6  
• Use of nano-immuno assay to generate rapid, quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens. (Abstract #10513)  
  Alice C. Fan  
• Discussion  
  Sofia Merajver, MD, PhD  

Brd. 7  
• A translational study to investigate the association between smoking-induced lung inflammation and lung metastases (LM) from breast cancer (BC). (Abstract #10514)  
  Patrick Glyn Morris  

Brd. 8  
• Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy during paclitaxel treatment. (Abstract #10515)  
  Daniel Louis Hertz  

Brd. 9  
• Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing. (Abstract #10516)  
  Xunhai Xu  

Brd. 10  
• Intraoperative detection of lymph node metastasis using one-step nucleic acid amplification (OSNA) in breast cancer patients: Effect on second surgery rate and delay for adjuvant therapy. (Abstract #10517)  
  Sophie Klingler
• Genetic variation in CYP19A1 and response to exemestane: Survival in early breast cancer in the Dutch TEAM trial. (Abstract #10518)
  
  Daniel Houtsma

• $^{64}$Cu-DOTA-trastuzumab-PET imaging in patients with HER2-positive breast cancer. (Abstract #10519)
  
  Kenji Tamura

• Discussion
  
  Manish Patel, DO

• Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese patients. (Abstract #10520)
  
  Shusuke Akamatsu

• BAP1: The first mutated gene causing familial uveal melanoma. (Abstract #10521)
  
  Johan Hansson

• The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers. (Abstract #10522)
  
  Kit Man Wong

• Prognostic significance of LINE-1 methylation level in the upper gastrointestinal cancer. (Abstract #10523)
  
  Yoshifumi Baba

• Discussion
  
  James M. Ford, MD

• Next-generation sequencing of FFPE solid tumor specimens for clinical use. (Abstract #10524)
  
  Roman Yelensky

• Prospective study of oncogenic mutations in circulating cell-free DNA (cfDNA) using a multiplex sequencing platform for patient (pt) allocation to phase I clinical trials. (Abstract #10525)
  
  Michael Ong

• Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network. (Abstract #10526)
  
  Masyar Gardizi

• Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker females with pulmonary adenocarcinoma. (Abstract #10527)
  
  Xiaoxia Chen

• New microRNA-based diagnostic test for lung cancer classification. (Abstract #10528)
  
  Ranit Aharonov
- Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment. (Abstract #CRA10529)
  
  Thomas Zander

- Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients (pts) with carcinoma of unknown primary site (CUP): Results of a prospective Sarah Cannon Research Institute (SCRI) trial. (Abstract #10530)
  
  Frank A. Greco

- Discussion
  
  David Paul Carbone, MD, PhD

---

**Session Title:** Breaching the Castle Wall: The Blood-Brain Barrier

**Session Type:** Education Session

**Time:** 9:45 AM - 11:00 AM

**Location:** E354b

- The Structure and Function of the Blood-Brain Barrier in Normal Brain and Brain Tumors
  
  William F. Elmquist, PhD, PharmD (Chair)

- Clinical Application and Limits for Small Molecules, Antibodies, and Immunotherapies in Brain Metastases
  
  John F. Deeken, MD

- Inclusion of Patients with Brain Metastases in Clinical Trials
  
  Patricia LoRusso, DO

---

**Session Title:** Genetic Counseling of the Patient with Pediatric Cancer

**Session Type:** Education Session

**Time:** 9:45 AM - 11:00 AM

**Location:** S504

- Rare Tumors with Underlying Genetic Predispositions
  
  Joshua David Schiffman, MD (Chair)

- Psychosocial Issues Surrounding Genetic Testing of Patients with High-Risk Pediatric Cancer
  
  Kim Nichols, MD

- Who, What, Where, When, and Why to Refer Patients with Pediatric Cancer for Genetic Counseling
  
  Sara Knapke, MS

---

**Session Title:** Global Perspective of Locally Advanced Gastric Cancer: Different Treatment Paradigms and Their Rationale

**Session Type:** Education Session

**Time:** 9:45 AM - 11:00 AM

**Location:** S406

- Discussion of the Different Surgical Approaches to Gastric Cancer: East versus West—Does This Have an Impact on Diverse Patient Outcomes
  
  Sam S. Yoon, MD

- Review of the Various Treatment Approaches for Locally Advanced Gastric Cancer: Perioperative Management, Postoperative Chemotherapy, and Postoperative Chemoradiotherapy
  
  Yoon-Koo Kang, MD, PhD

- Regional Differences in Gastric Cancer Outcomes: Is It Disease Biology or Disease Management?
  
  Manish A. Shah, MD (Chair)

---

**Session Title:** Leveraging Virtual Patient Communities for Optimal Clinical Care and Research
**Session Type:** Education Session  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E353

- Getting Off the Sidelines: Physician Engagement Online to Complement Dr. Google  
  *Howard Jack West, MD (Chair)*
- Dynamics of Partnerships between Professionals and Patient Online Communities to Accelerate Clinical Research and Improve Care  
  *George D. Demetri, MD*
- E-patients as the Most Underutilized Resource in Cancer Care  
  *Dave Debronkart*

---

**Session Title:** Translating Biologic Discoveries into Clinical Trials  
**Session Type:** Education Session  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E354a

- Genomics and Proteomics Technology in Biomarker Discovery  
  *Christine H. Chung, MD*
- Prognostic and Predictive Biomarkers in Head and Neck Cancer Clinical Trials  
  *Lisa F. Licitra, MD (Chair)*
- What Are the Important Early-Phase Trials in SCCHN  
  *Lillian L. Siu, MD*

---

**Session Title:** Cancer: Getting on Your Nerves  
**Session Type:** Clinical Science Symposium  
**Time:** 9:45 AM - 11:15 AM  
**Location:** S100a

- Chair  
  *Julia Howe Rowland, PhD*
- CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN). (Abstract #CRA9013)  
  *Ellen M. Lavoie Smith*
- Falls, physical performance deficits, and functional losses in cancer survivors with chemotherapy-induced neuropathy (CIPN): A University of Rochester CCOP study. (Abstract #9014)  
  *Supriya Gupta Mohile*

- Discussion  
  *Charles L. Loprinzi, MD*
- Rates and risks of suicidality in young adults (YAs) with advanced cancer. (Abstract #9015)  
  *Kelly Marie Trevino*
- Patterns of antidepressant use in cancer patients (pts): An analysis from SOAPP (ECOG E2Z02: Symptom Outcomes and Practice Patterns). (Abstract #9016)  
  *Judith Manola*

- Discussion  
  *David Spiegel, MD*

---

**Session Title:** Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy  
**Session Type:** Oral Abstract Session  
**Time:** 9:45 AM - 12:45 PM  
**Location:** E Hall D1

- Co-Chair  
  *Stephen K. L. Chia, MD*
• Co-Chair
  Joseph A. Sparano, MD
• NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (Abstract #LBA1000)
  Sandra M. Swain
• Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial. (Abstract #1001)
  Miguel Martin
• CALGB 40502/NCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). (Abstract #CRA1002)
  Hope S. Rugo
• A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119). (Abstract #1003)
  Young-Hyuck Im
• Discussion
  Kathy Miller, MD
• RTOG 9804: A prospective randomized trial for “good risk” ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS) (Abstract #1004)
  Beryl McCormick
• Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study. (Abstract #1005)
  Sunil S. Badve
• Discussion
  Eun-Sil Shelley Hwang, MD, MPH
• Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). (Abstract #1006)
  Ayca Gucalp
• Use of microRNA (miR) expression profiling to identify distinct subclasses of triple-negative breast cancers (TNBC). (Abstract #1007)
  Charles L. Shapiro
• Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG. (Abstract #1008)
  Maggie Chon U. Cheang
• Discussion
  Melinda L. Telli, MD

**Session Title:** Genitourinary Cancer (Prostate)

**Session Type:** Oral Abstract Session

**Time:** 9:45 AM - 12:45 PM

**Location:** E Arie Crown Theater

• Co-Chair
  Julie Nicole Graff, MD

• Co-Chair
  Mark N. Stein, MD
• Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110). (Abstract #4509)
  
  Malcolm David Mason

• Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. (Abstract #4510)
  
  Fred Saad

• SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). (Abstract #4511)
  
  David I. Quinn

• Discussion
  
  Eric Jay Small, MD

• Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). (Abstract #LBA4512)
  
  Chris Parker

• Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). (Abstract #4513)
  
  Matthew Raymond Smith

• A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). (Abstract #4514)
  
  Kim N. Chi

• Discussion
  
  Karim Fizazi, MD, PhD

• Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy. (Abstract #4515)
  
  Susan Halabi

• A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer. (Abstract #4516)
  
  William K. Oh

• 18F-16β-fluoro-5α-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC). (Abstract #4517)
  
  Karen A. Autio

• Discussion
  
  Phillip G. Febbo, MD